Navigation Links
Pevion's Therapeutic Candida Vaccine Shows Robust Systemic and Mucosal Immunogenicity, While Epidemiological Survey Confirms Excellent Market Potential
Date:10/11/2011

was performed in the US and the five largest European markets by Ipsos Health, a leader in the field of independent market research.

"The consistency of the Ipsos survey results across countries and with previous studies is very convincing. RVVC is a common problem throughout the Western world," says Prof. Betsy Foxman, a leading RVVC epidemiologist from the University of Michigan School of Public Health, Ann Arbor, USA. "41% of women surveyed reported a least one episode of vulvovaginal candidiasis. Of those, one in five had a 12-month period with 4 or more yeast infections. Therefore, PEV7 has the potential to address a strong unmet medical need."

"PEV7 is a first-in-class therapeutic vaccine to address this widespread and highly debilitating disease," states Evert Kueppers, CEO of Pevion. "Based on the positive data from our clinical study, we advance both product and business development activities for the PEV7 program at full speed."

About RVVC

Recurrent vulvovaginal candidiasis (RVVC), also known as chronic recurrent thrush, is a largely unrecognized but highly debilitating condition, which affects 7% of adult women. It is defined as four or more acute episodes of symptomatic vulvovaginal candidiasis within a 12 months period. Clinical symptoms are vulvovaginal inflammation, most often dominated by severe itching, and other symptoms causing extreme discomfort and pain. The quality of life of RVVC patients is strongly impacted, both physically and psychologically. A significant proportion of patients suffer over many years without perspective for any amelioration or cure from permanently present painful disease symptoms, impeded activities including social life and work, partnership problems, and difficulties or impossibility to talk about it. Over time, accumulating frustration leads to loss of self esteem, desperation, and in approximately a third of patients, to depression. Cure rates of RVVC with available antifungal drug therapy
'/>"/>

SOURCE Pevion Biotech AG
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. United Therapeutics Subsidiary Enters Into Contract With National Institutes of Health for Award of up to $45 Million to Support Glycobiology Antiviral Program
2. Kylin Therapeutics Receives Notice of Allowance for Second U.S. Patent Covering Delivery of Therapeutic RNA and pRNAi Technology
3. Orexigen® Therapeutics Announces Multiple Contrave® Data Presentations at the 29th Annual Scientific Meeting of The Obesity Society
4. Halozyme Therapeutics to Present at the JMP Securities Healthcare Conference on September 28
5. ALS Therapy Development Institute and Aestus Therapeutics, Inc., Expand Collaboration on Development of Novel ALS Therapies
6. ShangPharma Subsidiary and Jiangsu Hengrui Medicine Partner in Therapeutic Antibody Research and Development
7. Healthpoint Biotherapeutics to Present at UBS Global Life Sciences Conference
8. PharmaVentures Engaged by Astex Therapeutics to Assist in the Divestment of US Facility
9. CMC Biologics Licenses Its CHEF1® Expression System to Oxford BioTherapeutics
10. Debiopharm and Ascenta Therapeutics, Inc. Announce An Exclusive License Agreement for the Development and Commercialization of the IAP (Inhibitor of Apoptosis Protein) Inhibitor AT-406 (Called Debio 1143 by Debiopharm) for the Treatment of Various T
11. FierceBiotech Names Pearl Therapeutics a 2011 Fierce 15 Biotech
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Rockville, MD (PRWEB) September 17, 2014 ... Small Business Innovation Research (SBIR) grant to support the ... award will provide ITI with approximately $255,000 over one ... a leading cause of food allergy, affect over one ... anaphylaxis behind peanut allergy. Tree nut exposure is also ...
(Date:9/17/2014)... , Sept. 17, 2014 Intarcia Therapeutics, ... data from a study of the cost and predictability ... 50 th Annual Meeting of the European Association ... session today, Christian Frois , Ph.D., of Analysis ... series of planned Intarcia-sponsored, retrospective studies to characterize the ...
(Date:9/17/2014)... LAUDERDALE, Fla. , Sept. 17, 2014 Alternative ... an agreement to form a Special Purpose Vehicle in partnership ... based Jatropha centric agro energy company. The SPV shall be ... registered entity with AFAI as majority shareholder. The SPV shall ... Africa , particularly Ethiopia . ...
(Date:9/17/2014)... FRANCISCO, Calif. , Sept. 17, 2014 ... a molecular diagnostics company pioneering the field of molecular ... to chief operating officer. Mr. Hall joined ... the company,s commercial entry into endocrinology. Since 2012, he ... as well as managed care and billing functions. As ...
Breaking Biology Technology:Immunomic Therapeutics Awarded SBIR Grant to Develop Multi-Nut Allergy Immunotherapy 2Immunomic Therapeutics Awarded SBIR Grant to Develop Multi-Nut Allergy Immunotherapy 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 2Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 4Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 5AFAI Signs Joint Venture Agreement With Jatro Greentech Inc. 2AFAI Signs Joint Venture Agreement With Jatro Greentech Inc. 3Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer 2Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer 3Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer 4
... This release is available in German . ... magic word in electronics. Dr. Willi Auwaerter and Professor Johannes ... Universitaet Muenchen (TUM), have now presented a novel molecular switch ... functionality of the switch is the position of a single ...
... Therapeutics, Inc. today announced that Ivan Bergstein, MD, the ... the Oppenheimer 22nd Annual Healthcare Conference on Wednesday, December ... Astoria Hotel in New York City. ... Inc. is a clinical stage biopharmaceutical company developing novel ...
... 2011 Syndax Pharmaceuticals, Inc. announced today ... study, demonstrated entinostat, a novel, oral small molecule inhibitor ... single agent in patients with relapsed or refractory Hodgkin,s ... 11, from 6:00 to 8:00 PM PT at the ...
Cached Biology Technology:The smallest conceivable switch 2Stemline Therapeutics, Inc. to Present at the Oppenheimer 22nd Annual Healthcare Conference 2Entinostat Demonstrates Activity in Hodgkin's Lymphoma 2Entinostat Demonstrates Activity in Hodgkin's Lymphoma 3Entinostat Demonstrates Activity in Hodgkin's Lymphoma 4Entinostat Demonstrates Activity in Hodgkin's Lymphoma 5
(Date:9/17/2014)... University] After decades of decline, grasses have returned ... the eye, the marsh in those places seems healthy ... key service of the marsh coastal protection ... the ecosystem function hasn,t come back," said ecologist Mark ... of the study in the journal Biological Conservation ...
(Date:9/16/2014)... Center for Children,s Environmental Health at the Mailman School ... association between childhood asthma and prenatal exposure to two ... Results appear online in the journal Environmental Health ... during pregnancy to higher levels of the chemicals, butylbenzyl ... percent and 78 percent increase in risk of developing ...
(Date:9/16/2014)... on September 13, 2014. The fire is human-caused and ... 2,300 acres in size and is mostly being fueled ... calm Monday night due to higher humidity. Yesterday ... beginning to construct a fireline on the West and North ... on the fire: , 7 20-person Crews, 4 Hot Shot ...
Breaking Biology News(10 mins):Cape Cod saltmarsh recovery looks good, falls short 2Cape Cod saltmarsh recovery looks good, falls short 3Phthalates heighten risk for childhood asthma 2Phthalates heighten risk for childhood asthma 3
... launched a key initiative to keep Europe at the forefront ... cell therapies to restore lost, damaged, or ageing cells and ... body,s ,master cells, that have not yet been programmed to ... of stem cells, and it is becoming clear that if ...
... (TWIC) Program, Ensures No Fraudulent Duplicate Enrollments ... Fla., June 17 ID Solutions, Inc., ... trusted,credential assurance, reported that it has been ... the Transportation Security Agency,s (TSA,s),TWIC program. The ...
... its latest state of the environment report, released ... environmental issues facing the NAFTA partners. The ... biodiversity and ecosystems, and pollution. Specific topics include ... vaquita porpoiseand the quality and quantity of water ...
Cached Biology News:European Science Foundation aims to strengthen 'regenerative medicine' 2ID Solutions Awarded Full-Production Order for Fingerprint Processing Software for TWIC 2New report looks at the state of the North American environment 2
... precision pressure regulator and pressurized syringe holder for ... Steady flow rate Microinjecting Fine ... Can be added to any new or existing ... manufacturer, even homemade. Connect to house air or ...
Chicken polyclonal to UCK2 ( Abpromise for all tested applications). Antigen: Full length protein, corresponding to amino acids 1-261 of Human UCK2 Entrez Gene ID: 7371 Swiss Protein ID: ...
Physical Form: powder Color: white Removes FLAG peptide from N-terminal and Met-N-terminal fusion proteins. Supplied with optimized enterokinase buffer....
Features , Designed to assist users in applying domed caps to tube strips and plates , Minimises the pressure required to seal the caps effectively , Enables multiple tubes to be sealed simultaneousl...
Biology Products: